Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer

NCT07066995 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT07066995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07066995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 29, 2025
Completion date
December 28, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic cancer non-resectable, pancreatic cancer stage iv, pancreatic carcinoma